Treatments for SMA

There are currently three treatments for SMA approved in Europe. All increase the production of SMN, a protein essential for the survival of motor neurons.

Evrysdi: This compound is marketed by the pharmaceutical company Roche and approved for the treatment of SMA in Europe in March 2021 by the European Commission

Spinraza™: This compound is marketed by the pharmaceutical company Biogen and was approved for the treatment of SMA in Europe in June 2017 by the European Commission

ZolgensmaZolgensma™: This compound is marketed by the pharmaceutical company Novartis Gene Therapies (AveXis) and approved for the treatment of SMA in Europe in May 2020 by the European Commission

 

More information